Journal
JOURNAL OF NEURAL TRANSMISSION
Volume 126, Issue 6, Pages 723-729Publisher
SPRINGER WIEN
DOI: 10.1007/s00702-019-02016-w
Keywords
Parkinson's disease; Dopamine plasma membrane transport proteins; Neuroimaging; Obesity
Categories
Funding
- Michael J. Fox Foundation for Parkinson's Research
- AbbVie
- Avid
- Biogen
- Bristol-Myers Squibb
- COVANCE
- GE Healthcare
- Genentech
- GlaxoSmithKline
- Lundbeck
- Lilly
- Merck
- Meso Scale Discovery
- Pfizer
- Piramal
- Roche
- Sanofi Genzyme
- Servier
- TEVA
- UCB
- Pusan National University
Ask authors/readers for more resources
Fluctuating body weight is a commonly reported nonmotor feature in patients with Parkinson's disease (PD). We hypothesised that striatal dopamine transporter (DAT) density at the time of diagnosis might play an important role in weight regulation in patients with PD. DAT density was measured from I-123-FP-CIT single-photon emission computed tomography. Region-of-interest analyses were performed to measure the specific binding of I-123-FP-CIT to DAT, and the putamen-to-caudate nucleus ratio (PCR) was calculated. Body weight was measured at baseline (W0) and at 48months (W48). We classified subjects into three groups: weight loss, stable, and weight gain. In final analyses, 163 patients (106 men, 57 women) were included. PCR significantly differed by group in men, but not in women or across all patients. In men, PCR was slightly negatively associated with the percentage change in weight. No such correlation was found across all patients or in women. In univariate and multivariate logistic regression analyses, low PCR was associated with future weight gain in men with PD but not in women. In conclusion, striatal DAT availability at the time of diagnosis could predict subsequent weight change in men with PD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available